TrumpRx slashes drug prices up to 97%, making $756 Plavix just $16 and shocking Big Pharma

TrumpRx marks a historic turning point in prescription drug pricing, slashing medication costs by up to 97% through landmark deals announced today. Nine major pharmaceutical manufacturers have agreed to slash prices on essential medications under a new Most-Favored-Nation (MFN) pricing model. Patients will see dramatic savings on everything from blood thinners to hepatitis treatments when purchasing directly through the TrumpRx platform.

TrumpRx Slashes Drug Prices With Historic Pharma Deals

President Trump announced massive price reductions across nine major pharmaceutical manufacturers today, marking the largest coordinated drug pricing initiative to date. The Most-Favored-Nation pricing model ensures Americans pay the lowest prices available in other developed nations, ending what Trump describes as industries’ practice of subsidizing foreign countries through inflated U.S. prices.

The December 19 announcement reveals stunning savings on chronic condition treatments. Sanofi’s blood thinner Plavix drops from $756 to just $16, while insulin products will cost patients $35 per month. Bristol Myers Squibb cuts its HIV medication Reyataz from $1,449 to $217. Gilead Sciences slashes Hepatitis C treatment Epclusa from $24,920 to $2,425. These aren’t marginal reductions—they’re transformative price cuts.

Understanding Most-Favored-Nation Pricing and TrumpRx Platform

The MFN framework forces manufacturers to price medications sold in America at levels matching the lowest international prices. TrumpRx, launching in early 2026, operates as a direct-to-consumer platform connecting patients with these discounted prices. Unlike traditional insurance or pharmacy middlemen, the system eliminates layers of markups and intermediaries driving up costs.

Each participating company commits to deep discounts when patients purchase directly through the platform. Merck’s diabetes drug Januvia falls from $330 to $100. GSK’s popular asthma inhaler Advair Diskus 500/50 drops from $265 to $89. Novartis’s multiple sclerosis medication Mayzent plunges from $9,987 to $1,137. These reductions apply immediately upon launch and benefit all Americans, not just seniors on Medicare.

Medicaid Patients and Low-Income Americans See Immediate Benefits

The agreements guarantee every state Medicaid program access to MFN pricing, creating billions in taxpayer savings. Low-income beneficiaries will experience unprecedented pharmaceutical cost relief through expanded access to these discounted medicines. The framework ensures vulnerable populations don’t lose access to critical treatments while government budgets stabilize.

Each of the nine companies commits to providing MFN pricing on all new innovative medicines brought to market. This contractual obligation prevents future price inflation and establishes a precedent future manufacturers must follow. Foreign nations can no longer leverage price controls to free ride on American innovation, Trump administration officials stated during the announcement.

National Health Security Through American Manufacturing Investment

The pharmaceutical manufacturers involved pledge at least $150 billion in collective U.S. manufacturing investments in the near term. Beyond price reductions, companies are donating active pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign suppliers. GSK contributes 98.8 kilograms of albuterol for rescue inhalers. Bristol Myers Squibb donates 6.5 tons of apixaban (Eliquis ingredient). Merck contributes 3.5 tons of ertapenem for treating complex bacterial infections.

This dual approach simultaneously addresses affordability and supply chain vulnerability. American patients gain affordable access to essential medications while the nation builds stockpiles to prepare for emergencies and reduce dependence on foreign pharmaceutical nations.

Will these drug price deals stay permanent, and what happens after 2026?

The agreements appear structured for long-term commitment, with contractual obligations extending to all future innovative drugs from participating companies. These aren’t temporary promotional prices but contractual MFN frameworks requiring sustained discounting. The nine participating manufacturers have committed to maintaining these pricing structures across their entire portfolios as new products launch.

Once TrumpRx launches in early 2026, patients can access these prices immediately through the direct-to-consumer platform. Medicaid access begins now, providing immediate relief for low-income beneficiaries. The timeline ensures comprehensive national coverage without delay, signaling the administration’s commitment to rapid implementation of these historic price reductions.

Patrick Graham

Patrick Graham is a business and finance journalist translating Wall Street’s complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world’s biggest moves.